with respect to their inclination to cyclize, and to compare the
native with non-native ligation sites. It also has potential for the
determination of the native cyclization site if it is not known. As
an analog of the tetrahedral intermediate in amide formation,
the macrocyclic hemiaminal is of particular interest. Notably,
a comparison of the TycA hemiaminal and the native amide
with respect to biological activity will help the understanding of
the TycA structure–activity relationship. We are confident that
the examination of further lactams should reveal more details,
which may help us to better understand the determinants of
macrocyclization processes.
NOE-based molecular modeling
The structure calculations of W[R-CH(OH)NH]–TycA were car-
ried out as described previously6,18 using the program package
HyperChem19 with MM+ force field and without explicit water
included. The NOE-derived distances that were used as restraints
are listed in Table S4 in the ESI.† Ten snapshots from a 10 ¥
10 ps molecular dynamics simulation (step size 1 fs, 300 K)
were averaged and the resulting structure was allowed to relax
without restraints to verify the plausibility. The resulting structure
is depicted in Fig. 2, and the acquired distances are listed in
Table S4 in the ESI.†
Experimental section
Acknowledgements
Peptide synthesis
We are grateful to Dr U. Linne for his assistance with
HPLC and ESI-MS measurements. Financial support was pro-
vided by the Deutsche Forschungsgemeinschaft (DFG) and by
the Studienstiftung des Deutschen Volkes (Ph.D. scholarship
for S.E.).
The synthesis of Tyrocidine A aldehyde was carried out ac-
cording to a protocol described previously,16 starting from H–
R
Thr–Gly–NovaSynꢀ TG resin (Novabiochem) preloaded with
leucine amino aldehyde. The chain extension was carried out
by automated Fmoc solid phase synthesis. After assembly of
the target sequence and removal of protecting groups, the crude
peptide aldehyde was cleaved from resin, precipitated in hexane,
and purified by preparative HPLC. The identity of the product
obtained after lyophilization was confirmed by analytical HPLC-
ESI-MS. A sample of cyclized TycA in basic aqueous solution
was also controlled via ESI-MS. Further experimental details, the
HPLC trace of the purified peptide, as well as high-resolution ESI-
MS spectra of all linear and cyclic compounds, are provided in the
ESI.†
References
1 E. M. Nolan and C. T. Walsh, ChemBioChem, 2009, 10, 34–53.
2 F. Kopp and M. A. Marahiel, Nat. Prod. Rep., 2007, 24, 735–
749.
3 E. M. Driggers, S. P. Hale, J. Lee and N. K. Terrett, Nat. Rev. Drug
Discovery, 2008, 7, 608–624.
4 J. Blankenstein and J. Zhu, Eur. J. Org. Chem., 2005, 1949–1964.
5 T. Golakoti, W. Y. Yoshida, S. Chaganty and R. E. Moore, J. Nat.
Prod., 2001, 64, 54–59.
6 S. Enck, F. Kopp, M. A. Marahiel and A. Geyer, ChemBioChem, 2008,
9, 2597–2601.
NMR analytics
7 X. Bu, X. Wu, G. Xie and Z. Guo, Org. Lett., 2002, 4, 2893–2895.
=
8 This modified TycA is abbreviated to W[C N]–TycA. The fact that
Homo- and heteronuclear NMR measurements were carried
out using a Bruker Avance DRX600 spectrometer operating at
600.13 MHz (1H) and 150.90 MHz (13C), respectively, with a 5 mm
BBI probe head. All chemical shifts are given in parts per million
(ppm). For water suppression, the double pulsed field-gradient
spin echo (WATERGATE) sequence17 was applied, which had
also been appropriate in preceding studies.6 All measurements
described were carried out with the same NMR sample to prove
the reversibility of the system. TycA–CHO was dissolved in a
partially deuterated KH2PO4/H3PO4 buffer solution (H2O/D2O
5 : 1) at pH 3.0. The pH was set to the desired value by addition
of solid Na2CO3 and aqueous H3PO4, respectively. For the
temperature-dependent series of measurements, 10 K steps (290–
330 K) were chosen and the sample was allowed to equilibrate in
the spectrometer for 1 h. In the ESI,† further details, including
assigned NMR spectra, as well as chemical shifts and temperature
gradients, are given.
no position for the modified tether is given indicates that the native
cyclization position is retained.
9 M.-C. Kuo and W. A. Gibbons, J. Biol. Chem., 1979, 254, 6278–
6287.
10 M.-C. Kuo and W. A. Gibbons, Biophys. J., 1980, 32, 807–836.
11 R. M. Kohli, J. W. Trauger, D. Schwarzer, M. A. Marahiel and C. T.
Walsh, Biochemistry, 2001, 40, 7099–7108.
12 A. P. Tonge, P. Murray-Rust, W. A. Gibbons and L. K. McLachlan,
J. Comput. Chem., 1988, 9, 522–538.
13 N. Zhou, P. Mascagni, W. A. Gibbons, N. Niccolai, C. Rossi and H.
Wyssbrod, J. Chem. Soc., Perkin Trans. 2, 1985, 581–587.
14 J. W. Trauger, R. M. Kohli and C. T. Walsh, Biochemistry, 2001, 40,
7092–7098.
15 L. M. Amzel, Proteins: Struct., Funct., Genet., 1997, 28, 144–149.
16 F. Kopp, C. Mahlert, J. Gru¨newald and M. A. Marahiel, J. Am. Chem.
Soc., 2006, 128, 16478–16479.
17 T.-L. Hwang and A. J. Shaka, J. Magn. Reson., Ser. A, 1995, 112,
275–279.
18 M. Haack, S. Enck, H. Seger, A. Geyer and A. G. Beck-Sickinger,
J. Am. Chem. Soc., 2008, 130, 8326–8336.
19 HyperChem, Hypercube, Inc., Gainesville, FL, 2000.
This journal is
The Royal Society of Chemistry 2010
Org. Biomol. Chem., 2010, 8, 559–563 | 563
©